193354-16-4Relevant articles and documents
Encapsulating Cobalt into N-Doping Hollow Frameworks for Efficient Cascade Catalysis
Yun, Ruirui,Zhang, Beibei,Qiu, Chuang,Ma, Ziwei,Zhan, Feiyang,Sheng, Tian,Zheng, Baishu
supporting information, p. 9757 - 9761 (2021/06/30)
The development of nonprecious catalysts for hydrogenation of organic molecules is of great importance in heterogeneous catalysis. Herein, we report a series of N-doped hollow carbon frameworks encompassing cobalt nanoparticles (denoted as Co@NHF-900) constructed as a new kind of reusable catalyst for this purpose by pyrolysis of ZIF-8@Co-dopamine under Ar atmospheres. Notably, the framework of ZIF-8 is essential for efficient catalyst by providing a carbon framework to support Co-dopamine. The experimental results reveal that the ZIF-8 renders a large hollow place within the catalysts, allowing the enrichment of the substrate and windows of the hollow structure and the ease of mass transfer of products during the reaction. All of the virtues made Co@NHF-900 a good candidate for hydrogenation of quinolines with high activity (TOF value of 119 h-1, which is several times than that of akin catalysts) and chemoselectivity.
Dual-Active-Sites Design of Co@C Catalysts for Ultrahigh Selective Hydrogenation of N-Heteroarenes
Zhang, Sai,Gan, Jie,Xia, Zhaoming,Chen, Xiao,Zou, Yong,Duan, Xuezhi,Qu, Yongquan
supporting information, p. 2994 - 3006 (2020/09/04)
The dual-active-sites Co@C catalyst provides a general powerful strategy to break the limitation of scaling relation on traditional metal surfaces and thus affords unprecedentedly selective hydrogenation of various N-heteroarenes as well as high activity and stability. A porous carbon shell not only allows H2 diffusion to Co sites for activation but also blocks accessibility of N-heteroarenes, and the hydrogenation of N-heteroarenes is achieved on carbon by the spilled hydrogen from Co sites. In addition, the presence of surface/subsurface carbon at the Co sites shows high anti-sulfur poisoning and anti-oxidant capability. Ideal heterogeneous metal hydrogenation catalysts are featured by simultaneously high activity, selectivity, and stability. Herein, we report a general yet powerful strategy to design and fabricate dual-active-sites Co@C core-shell nanoparticle for boosting selective hydrogenation of various N-heteroarenes. It can break the limitation of scaling relation on traditional metal surfaces, and thus afford unprecedentedly high selectivity, activity, and stability. Combining kinetics analysis and DFT calculations with multiple techniques directly unveil that the critical porous carbon shell with a pore size of 0.53 nm not only allows H2 diffusion to Co sites for activation and blocks accessibility of N-heteroarenes but also catalyzes hydrogenation of N-heteroarenes via hydrogen spillover from Co sites. In addition, the presence of surface/subsurface carbon at the Co sites shows high anti-sulfur poisoning and anti-oxidant capability. This work is valuable for guiding the design and manipulation of cost-effective and robust hydrogenation catalysts. Our research can provide an environmentally friendly approach to afford unprecedentedly selective N-heteroarenes hydrogenation, which will greatly reduce the resource and energy consumption and decrease the amount of waste discharge and water pollution. Therefore, these results could help in achieving the “Clean water and sanitation” goal in the 10 UN Sustainable Development Goals. Meanwhile, the products of N-heteroarenes hydrogenation are the core structural motifs in both fine and bulk chemicals, which will make our life more beautiful. Thus, our research also benefits the “Good health and well-being” goal.
S1P RECEPTORS MODULATORS
-
Page/Page column 56, (2010/04/30)
The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.
